WO2025078881 - ANTI-CLAUDIN 18.2 ANTIBODY DRUG CONJUGATES COMPRISING TOPOISOMERASE I INHIBITOR AND USES THEREOF

National phase entry is expected:
Publication Number WO/2025/078881
Publication Date 17.04.2025
International Application No. PCT/IB2024/000570
International Filing Date 11.10.2024
Title [English] ANTI-CLAUDIN 18.2 ANTIBODY DRUG CONJUGATES COMPRISING TOPOISOMERASE I INHIBITOR AND USES THEREOF [French] CONJUGUÉS MÉDICAMENT-ANTICORPS ANTI-CLAUDINE 18.2 COMPRENANT UN INHIBITEUR DE TOPOISOMÉRASE I ET LEURS UTILISATIONS
Applicants ** LIGACHEM BIOSCIENCES INC. 10, Gukjegwahak 10-ro Yuseong-gu Daejeon 34002, KR LEGOCHEM BIOSCIENCES INC. 10, Gukjegwahak 10-ro Yuseong-gu Daejeon 34002, KR
Inventors ** JANG, Tae Ik 10, Gukjegwahak 10-ro Yuseong-gu Daejeon 34002, KR PARK, Chang Sik 10, Gukjegwahak 10-ro Yuseong-gu Daejeon 34002, KR BAEK, Eun Ji 10, Gukjegwahak 10-ro Yuseong-gu Daejeon 34002, KR SONG, Ho Young 10, Gukjegwahak 10-ro Yuseong-gu Daejeon 34002, KR CHAE, Sang Eun 10, Gukjegwahak 10-ro Yuseong-gu Daejeon 34002, KR PARK, Se Yeon 10, Gukjegwahak 10-ro Yuseong-gu Daejeon 34002, KR CHUNG, Chul-Woong 10, Gukjegwahak 10-ro Yuseong-gu Daejeon 34002, KR
Priority Data 10-2023-0136955  13.10.2023  KR 10-2024-0035926  14.03.2024  KR
Application details
International Searching Authority
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country Stages Total
China Filing 2958
EPO Filing, Examination 33939
Japan Filing 570
South Korea Filing 612
USA Filing, Examination 14235
+ Add country
MasterCard Visa
Total: 52314
QUOTE TO EMAIL ONLINE QUOTE
Abstract [English] The present disclosure relates to an antibody-drug conjugate (ADC) targeting human Claudin 18 isoform 2 (CLDN 18.2) and use thereof, and more particularly, to an ADC including an antibody or antigen-binding fragment thereof that binds to human CLDN18.2, and a topoisomerase I inhibitor (e.g., a camptothecin); and use of ADCs for the treatment and/or treatment of diseases, more particularly, hyperproliferative and/or angiogenic diseases, such as cancer diseases. [French] La présente divulgation concerne un conjugué anticorps-médicament (ADC) ciblant l'isoforme 2 de la claudine 18 (CLDN 18.2) humaine et son utilisation, et plus particulièrement, un ADC comprenant un anticorps ou un fragment de liaison à l'antigène de celui-ci qui se lie à la CLDN18.2 humaine, et un inhibiteur de topoisomérase I (par exemple, une camptothécine) ; et l'utilisation d'ADC pour le traitement et/ou le traitement de maladies, plus particulièrement, de maladies hyperprolifératives et/ou angiogéniques, telles que des maladies cancéreuses.